Kurt von Emster
SlowingNamed in filings at Venbio Select
- Board seats filed
- 8
all filings on record
Named in filings at Venbio Select
all filings on record
last 24 months
from a verified or cited source
| Jasper Therapeutics | Not yet classified | July 2026 | None on file |
| Iambic Therapeutics | Not yet classified | September 2023 | None on file |
| Vera Therapeutics | Biotech & pharma | October 2020 | Longitude 103.8 East, Longitude Capital, Longitude Prime, Sofinnova Venture Partners, Westlake Biopartners |
| Orbus Therapeutics | Biotech & pharma | July 2020 | Longitude 103.8 East, Longitude Capital, Longitude Prime, Prince Street |
| Attenua | Not yet classified | April 2018 | None on file |
| CRISPR Therapeutics AG | Biotech & pharma | October 2016 | Versant Venture Capital |
| CymaBay Therapeutics | Not yet classified | August 2015 | None on file |
| SutroVax | Biotech & pharma | July 2015 | Longitude 103.8 East, Longitude Capital, Longitude Prime |
The company and date are what the SEC filing shows, not a statement of investment thesis. A partner can sit on a board for reasons that say nothing about what their firm funds today. The sector is not a filing value: it is Lev’s own classification of each company, shown only when we found a specific, checkable source for it; otherwise it reads “Not yet classified.” “Also on the board from” names another tracked firm with a partner on the same board, both with a clean identity match. It is not a claim either firm led or co-led the round, and “None on file” means no other tracked firm’s partner shares this specific board seat, not that no one else invested. Sorted newest first by default; click a column to change it. Something wrong? Tell us.
Classified sectors of companies where filings name Kurt von Emster on the board, based on 4 filed seats with a verified or cited source.
4 more filed seats not yet classified, left out of the shares above.